Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Palvella Therapeutics stock last closed at $122.06, down 10.64% from the previous day, and has increased 349.08% in one year. It has overperformed other stocks in the Biotechnology industry by 3.89 percentage points. Palvella Therapeutics stock is currently +569.74% from its 52-week low of $18.23, and -19.26% from its 52-week high of $151.18.
There are currently 11.84M PVLA shares outstanding. The market cap of PVLA is $1.44B. In the last 24 hours, 483,000 PVLA shares were traded.
How to Buy Palvella Therapeutics Stock
Not sure how to invest in Palvella Therapeutics stock? Here's how.
Figure out where to buy Palvella Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you choose where to buy Palvella Therapeutics stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Deposit money your investment account: Select your payment method and add your info.
Analyze Palvella Therapeutics stock: The Palvella Therapeutics ticker symbol is PVLA. Is Palvella Therapeutics stock a good investment? Should you buy shares of PVLA? How do PVLA's underlying business fundamentals look? Do top analysts think Palvella Therapeutics is a good buy? Why has PVLA's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if PVLA is a good stock to buy).
Make your PVLA purchase: Decide if you will purchase PVLA shares at the current market price or use a limit order to purchase PVLA shares at a particular price.
Get the latest scoop on your investment in PVLA: Create a watchlist to monitor your investment in Palvella Therapeutics shares.
Step 1: Figure out where to buy Palvella Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy PVLA shares.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to global financial markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal information so you can buy PVLA today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Palvella Therapeutics stock
Once you have selected the best place to buy Palvella Therapeutics stock, it's crucial to analyze their stock before you invest, so you truly understand the risk and opportunity.
Palvella Therapeutics Numbers
PVLA Price
$122.06
1w %
-9.17%
1y %
349.08%
5y %
-44.72%
P/E
-75.35x
P/B
37.35x
P/S
-24,412x
PEG
N/A
Revenue
-$53.00k
Earnings
-$35.07M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$1.44B
Next Earnings
N/A
Next Dividend
N/A
PVLA Overview
WallStreetZen was designed to help part-time investors perform better fundamental analysis in less time.
PVLA has cash burn of 22590000. It has sufficient cash and short-term investments to cover this for at least one year.
PVLA profit margin has gone up from -57.4% to 66,162.3% in the past year.
There are more short-term assets than short-term liabilities on the PVLA balance sheet.
Total PVLA debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than long-term liabilities on the PVLA balance sheet.
PVLA has $63.57M in cash and short term investments. This is sufficient to cover its annual cash burn of $22.59M.
Negative Financial Indicators:
PVLA has a relatively high debt to equity ratio of 0.73.
Do analysts think it's a good time to buy PVLA stock
Out of 12 Wall Street analysts who research PVLA, the consensus analyst rating on Palvella Therapeutics is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Latest PVLA Analyst Upgrades/Downgrades
Whitney Ijem, a top 5% analyst from Canaccord Genuity maintains PVLA with a strong buy rating and raises their PVLA price target from $148.00 to $204.00, on Dec 16, 2025.
Canaccord Genuity's Whitney Ijem raised their price target on Palvella Therapeutics (NASDAQ: PVLA) by 37.8% from $148 to $204 on 2025/12/16. The analyst maintained their Strong Buy rating on the stock.
Hiking their price target on Palvella Therapeutics, Ijem called the initial Ph2 data for QTORIN rapamycin's 2nd indication, cutaneous venous malformation (cVM), a win.
The analyst detailed that the company had been expecting at least a 30% response rate, so the 73% of patients who improved on the cVM-IGA at Week 12 far outstripped the metric, meaning it will not be difficult or expensive to design an efficient pivotal study.
Ritu Baral, a bottom 11% analyst from TD Cowen maintains PVLA with a strong buy rating and raises their PVLA price target from $97.00 to $133.00, on Dec 16, 2025.
Kaveri Pohlman, a top 23% analyst from Clear Street initiates coverage on PVLA with a strong buy rating and announces their PVLA price target of $200.00, on Dec 5, 2025.
Albert Lowe, a top 26% analyst from Craig-Hallum initiates coverage on PVLA with a buy rating and announces their PVLA price target of $175.00, on Dec 4, 2025.
Annabel Samimy, a top 7% analyst from Stifel Nicolaus maintains PVLA with a strong buy rating and raises their PVLA price target from $87.00 to $145.00, on Nov 24, 2025.
No, Palvella Therapeutics doesn't provide an income stream by paying out dividends.
PVLA Social Trading Data
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your PVLA purchase
You have two main order types:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are mostly sufficient.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a specific dollar amount, use a limit order.
Click the Open Trade button and your broker will place your order.
If you want more help with investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Palvella Therapeutics share?
As of Mar 13, 2026, it costs $122.06 to buy one share of Palvella Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.082 shares of PVLA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.